Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Wittes

Showing results (1-10 of 122) with videos related to

Pageof 13
Sort By:
Epidemiologic Reviews|July 18, 2002
Sample size calculations for randomized controlled trialsJanet Wittes
Statistics in Medicine|May 4, 2004
Playing safe and preserving integrity: making the FDA model workJanet Wittes
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 18, 2005
Forming your phase III trial's data and safety monitoring board: a perspective on safetyJanet Wittes
Clinical Trials (London, England)|October 23, 2009
Comment on paper by Crowe et alJanet Wittes
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing inaction: preventing missing outcome data in randomized clinical trialsJanet Wittes
Circulation|February 25, 2009
On looking at subgroupsJanet Wittes
Journal of Biopharmaceutical Statistics|November 9, 2010
Comments on the FDA draft guidance on adaptive designsJanet Wittes
Circulation. Heart Failure|August 28, 2024
Reflections on the Win Ratio With Time-to-Event OutcomesJanet Wittes
Clinical Trials (London, England)|March 6, 2016
Commentary on Murray and HernánJanet Wittes
Nature Medicine|November 9, 2012
Clinical trials must cope better with multiplicityJanet Wittes
Pageof 13

Showing results (1-10 of 122) with videos related to

Sort By:
Pageof 13
Epidemiologic Reviews|July 18, 2002
Sample size calculations for randomized controlled trialsJanet Wittes
Statistics in Medicine|May 4, 2004
Playing safe and preserving integrity: making the FDA model workJanet Wittes
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 18, 2005
Forming your phase III trial's data and safety monitoring board: a perspective on safetyJanet Wittes
Clinical Trials (London, England)|October 23, 2009
Comment on paper by Crowe et alJanet Wittes
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing inaction: preventing missing outcome data in randomized clinical trialsJanet Wittes
Circulation|February 25, 2009
On looking at subgroupsJanet Wittes
Journal of Biopharmaceutical Statistics|November 9, 2010
Comments on the FDA draft guidance on adaptive designsJanet Wittes
Circulation. Heart Failure|August 28, 2024
Reflections on the Win Ratio With Time-to-Event OutcomesJanet Wittes
Clinical Trials (London, England)|March 6, 2016
Commentary on Murray and HernánJanet Wittes
Nature Medicine|November 9, 2012
Clinical trials must cope better with multiplicityJanet Wittes
Pageof 13